Actively Recruiting
A Comparative Examination of Depression Severity, Gender-Sensitive Depressive Symptoms, Psychological Resilience, and Stigma Levels in Women and Men With Major Depressive Disorder
Led by Eskisehir Osmangazi University · Updated on 2026-03-25
90
Participants Needed
1
Research Sites
30 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Major Depressive Disorder (MDD) is a common and serious mental health condition that affects mood, thoughts, behavior, and overall quality of life. This research aims to compare women and men diagnosed with MDD by examining depression severity, gender-sensitive depressive symptoms, self-stigma, perceived social stigma, and psychological resilience. The study seeks to better understand how gender differences influence the experience and management of depression, with the goal of informing more personalized mental health care. The study involves two groups of participants: women and men aged 18 to 65 years who have been diagnosed with MDD. Participants will be assessed at a single time point to evaluate various factors related to their depression, including the severity of symptoms and experiences of stigma and resilience. There are no interventions or treatments being tested in this observational study. Participants will complete assessments measuring depression severity, gender-sensitive depressive symptoms, self-stigma, perceived social stigma related to seeking psychological help, and psychological resilience. These evaluations will help researchers understand the relationships among these factors and how they differ between men and women. The total participation involves one baseline assessment during the study period ending in November 2026.
CONDITIONS
Brief Title
Gender Differences in Depression Severity, Gender-Sensitive Symptoms, Resilience, and Stigma in Major Depressive Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female patients aged 18 to 65 years
- Diagnosis of Major Depressive Disorder according to DSM-5 at the time of study participation
- Provision of voluntary informed consent
You will not qualify if you...
- Intellectual disability
- Severe neurological disorders
- Comorbid psychiatric diagnoses
- Depressive disorder secondary to an organic medical condition
- Depressive disorder secondary to substance use
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single assessment at baseline
Participants complete assessments measuring depression severity, gender-sensitive depressive symptoms, self-stigma, social stigma, and psychological resilience.
1 visit (in-person)
Duration - Up to study completion in November 2026
Participants are observed following initial assessments without active intervention.
Visits as per routine clinical care
Trial Site Locations
Total: 1 location
1
the Department of Psychiatry Outpatient Clinic at Eskişehir Osmangazi University Faculty of Medicine
Eskişehir, Eskişehir, Turkey (Türkiye), 26040
Actively Recruiting
Research Team
İ
İrem OZKAYNAK DAGLİ, Research assistant, M.D.
H
HARUN O SONKURT, Asst. Prof.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here